A detailed history of South Dakota Investment Council transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, South Dakota Investment Council holds 32,916 shares of COLL stock, worth $992,417. This represents 0.02% of its overall portfolio holdings.

Number of Shares
32,916
Previous 32,916 -0.0%
Holding current value
$992,417
Previous $1.06 Million 20.0%
% of portfolio
0.02%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$31.36 - $39.99 $3.92 Million - $4.99 Million
-124,856 Reduced 79.14%
32,916 $1.06 Million
Q1 2024

May 02, 2024

SELL
$31.23 - $40.91 $2.68 Million - $3.52 Million
-85,946 Reduced 35.26%
157,772 $6.13 Million
Q3 2023

Nov 07, 2023

SELL
$21.23 - $24.28 $111,542 - $127,567
-5,254 Reduced 2.11%
243,718 $5.45 Million
Q1 2023

May 10, 2023

SELL
$23.0 - $29.88 $749,800 - $974,088
-32,600 Reduced 11.58%
248,972 $5.97 Million
Q4 2022

Feb 07, 2023

BUY
$16.14 - $23.55 $124,681 - $181,923
7,725 Added 2.82%
281,572 $6.53 Million
Q3 2022

Nov 09, 2022

BUY
$15.46 - $20.1 $318,120 - $413,597
20,577 Added 8.12%
273,847 $4.39 Million
Q2 2022

Aug 11, 2022

BUY
$14.22 - $20.88 $490,334 - $719,984
34,482 Added 15.76%
253,270 $4.49 Million
Q1 2022

May 10, 2022

SELL
$17.2 - $22.5 $1.3 Million - $1.69 Million
-75,300 Reduced 25.6%
218,788 $4.46 Million
Q4 2021

Feb 08, 2022

BUY
$17.5 - $21.35 $173,425 - $211,578
9,910 Added 3.49%
294,088 $5.49 Million
Q3 2021

Nov 09, 2021

BUY
$17.75 - $25.39 $3.16 Million - $4.52 Million
177,996 Added 167.63%
284,178 $5.61 Million
Q2 2021

Aug 11, 2021

BUY
$21.74 - $25.28 $2.31 Million - $2.68 Million
106,182 New
106,182 $2.51 Million

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.03B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track South Dakota Investment Council Portfolio

Follow South Dakota Investment Council and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

News

Stay updated on South Dakota Investment Council with notifications on news.